Cambridge Healthtech Institute’s Inaugural
Drug Discovery Technologies
Enabling Disruptive Innovation
June 3-4, 2020
High costs and long timelines in biopharma R&D emphasize the need for novel technologies that enable new therapeutic platforms and a better understanding of disease. CHI’s Inaugural Drug Discovery Technologies conference is designed as a comprehensive
overview of current and emerging technologies and their providers. Each speaker will address a certain technology and its scientific implications in drug discovery and development programs.
Coverage will include, but is not limited to:
- Target ID technologies
- AI/ML and computational tools
- CRISPR-genome editing
- Complex cellular assays
- Histology, pathology, image analysis
- Synthetic biology
- RNAi cell lines
- Human biospecimen and biobanking
- Immune profiling and immune monitoring
- iPS cells for disease modeling
- In vivo and in vitro pharmacology
- Discovery pharmacokinetics
- Preclinical scanners and microscopy
- Multiplexed error-robust fluorescence in situ hybridization
If you would like to submit a proposal to give a presentation at this meeting, please click here.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Marina Filshtinsky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
For partnering and sponsorship information, please contact:
Manager, Business Development
Joseph Vacca, M.S.
Director, Business Development